Faculty of Medicine University of Porto, Porto (Portugal)
Follow
Contributor content
Presentation
Myocardial phosphoproteomics and single cardiomyocyte force measurements endorse DYRK1A as a candidate therapeutic target for incomplete reverse remodelling after aortic valve replacement
